Intellia Therapeutics Inc. Common Stock (NTLA)

About NTLA

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. T…

Sector

Health Care

Industry

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Employees

377

Website

www.intelliatx.com/

Fundamentals

1-day range

$12.68$13.49

Market cap

$1.50B

P/E (trailing)

—

P/E (forward)

-4.94

EPS (trailing)

$-3.36

Dividend yield

—

Beta

1.81

Avg. volume

4.85M

Forecasts

17 analyst ratings

Intellia Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• NTLA

  Intellia Therapeutics Inc. Common Stock

  $12.87

  ▼ 1.83%
  Market cap $1.50BP/E —
  $7.95$28.25
• NNNN

  Anbio Biotechnology Class A Ordinary Shares

  $7.64

  ▼ 1.80%
  Market cap $1.53BP/E 144.72
  $6.61$51.33
• ACHV

  Achieve Life Sciences Inc. Common Shares

  $8.09

  ▼ 1.16%
  Market cap $648.81MP/E —
  $2.62$8.61
• NEOG

  Neogen Corporation Common Stock

  $11.67

  ▼ 0.60%
  Market cap $2.59BP/E —
  $4.9$12.85
• TKNO

  Alpha Teknova Inc. Common Stock

  $7.13

  ▼ 2.46%
  Market cap $284.15MP/E —
  $1.91$7.84
• IMDX

  Insight Molecular Diagnostics Inc. Common Stock

  $4.16

  ▼ 3.03%
  Market cap $162.42MP/E —
  $2.33$8.51
• CDIO

  Cardio Diagnostics Holdings Inc. Common stock

  $1.84

  ▼ 1.60%
  Market cap $4.85MP/E —
  $0.97$7.91

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
  benzinga · 8/25/2026
• Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target
  Benzinga · 8/25/2026
• Tracking Cathie Wood's ARK Invest 13F Portfolio - Q2 2026 Update
  SeekingAlpha · 8/19/2026
• Intellia (NTLA) Q2 2026 Earnings Call Transcript
  Yahoo · 8/13/2026
• These Are the Stocks Wall Street Is Betting Against the Most
  Yahoo · 8/12/2026
• Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/7/2026
• NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
  Yahoo · 8/7/2026
• Intellia Therapeutics, Inc. Q2 2026 Earnings Call Summary
  Yahoo · 8/7/2026
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Yahoo · 8/7/2026

• John M. Leonard · August 21, 2026 · Sale

  2.8K @ $13
• John M. Leonard · August 20, 2026 · Sale

  19.9K @ $12.6
• Edward J. Dulac III · July 22, 2026 · Sale

  8.1K @ $11.25
• Edward J. Dulac III · July 2, 2026 · Sale

  4.7K @ $18
• Michael P. Dube · July 1, 2026 · Sale

  2.6K @ $16.78
• Jesse Goodman · June 9, 2026 · Grant

  13.3K
• Jesse Goodman · June 9, 2026 · Grant

  9.2K
• Georgia Keresty · June 9, 2026 · Grant

  13.3K
• Georgia Keresty · June 9, 2026 · Grant

  9.2K
• Muna Bhanji · June 9, 2026 · Grant

  13.3K
• Muna Bhanji · June 9, 2026 · Grant

  9.2K
• William J. Chase · June 9, 2026 · Grant

  13.3K
• William J. Chase · June 9, 2026 · Grant

  9.2K
• Brian Goff · June 9, 2026 · Grant

  13.3K
• Brian Goff · June 9, 2026 · Grant

  9.2K

Institutional Ownership

March 31, 2026

Total shares held

108.13M

Total value held

$1.37B

Institutional holders

300